0 33

Cited 0 times in

Hepatocellular Carcinoma Risk Steadily Persists Over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이혜원-
dc.contributor.author한광협-
dc.date.accessioned2020-06-17T00:47:27Z-
dc.date.available2020-06-17T00:47:27Z-
dc.date.issued2020-01-
dc.identifier.issn1055-9965-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/176124-
dc.description.abstractBackground: Long-term antiviral therapy (AVT) for chronic hepatitis B (CHB) reduces the risk of hepatocellular carcinoma (HCC). We assessed the temporal trends in the incidence of HCC over time during long-term AVT among Asian patients with CHB. Methods: Patients with CHB receiving entecavir/tenofovir (ETV/TDF) as a first-line antiviral were recruited from four academic hospitals in the Republic of Korea. We compared the incidence of HCC during and after the first 5 years of ETV/TDF treatment. Results: Among 3,156 patients, the median age was 49.6 years and males predominated (62.4%). During the follow-up, 9.0% developed HCC. The annual incidence of HCC per 100 person-years during the first 5 years (n = 1,671) and after the first 5 years (n = 1,485) was statistically similar (1.93% vs. 2.27%, P = 0.347). When the study population was stratified according to HCC prediction model, that is, modified PAGE-B score, the annual incidence of HCC was 0.11% versus 0.39% in the low-risk group (<8 points), 1.26% versus 1.82% in the intermediate-risk group (9-12 points), and 4.63% versus 5.24% in the high-risk group (≥13 points; all P > 0.05). A Poisson regression analysis indicated that the duration of AVT did not significantly affect the overall trend of the incidence of HCC (adjusted annual incidence rate ratio = 0.85; 95% confidence interval, 0.66-1.11; P = 0.232). Conclusions: Despite long-term AVT, the risk of HCC steadily persists over time among patients with CHB in the Republic of Korea, in whom HBV genotype C2 predominates. Impact: Careful HCC surveillance is still essential.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherAmerican Association for Cancer Research-
dc.relation.isPartOfCANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleHepatocellular Carcinoma Risk Steadily Persists Over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorYeon Seok Seo-
dc.contributor.googleauthorHan Ah Lee-
dc.contributor.googleauthorMi Na Kim-
dc.contributor.googleauthorEun Ju Lee-
dc.contributor.googleauthorHye Jung Shin-
dc.contributor.googleauthorYu Rim Lee-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorSoon Ho Um-
dc.contributor.googleauthorWon Young Tak-
dc.contributor.googleauthorYoung Oh Kweon-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSoo Young Park-
dc.identifier.doi10.1158/1055-9965.EPI-19-0614-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA02226-
dc.contributor.localIdA03318-
dc.contributor.localIdA03318-
dc.contributor.localIdA04268-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00441-
dc.identifier.eissn1538-7755-
dc.identifier.pmid31988073-
dc.identifier.urlhttps://cebp.aacrjournals.org/content/29/4/832.long-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor한광협-
dc.citation.volume29-
dc.citation.number4-
dc.citation.startPage832-
dc.citation.endPage837-
dc.identifier.bibliographicCitationCANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, Vol.29(4) : 832-837, 2020-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.